Data Insights

TAA06-UCAR-gammadeltaT by PersonGen BioTherapeutics (Suzhou) for Solid Tumor: Likelihood of Approval

TAA06-UCAR-gammadeltaT is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Solid Tumor. According to GlobalData,...

Data Insights

PA-317 by PersonGen BioTherapeutics (Suzhou) for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...

Likelihood of Approval and Phase Transition Success Rate Model - PA-317 in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

PA-317 by PersonGen BioTherapeutics (Suzhou) for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Anaplastic Large Cell Lymphoma (ALCL)....

Likelihood of Approval and Phase Transition Success Rate Model - PA-317 in Anaplastic Large Cell Lymphoma (ALCL)

Data Insights

PA-317 by PersonGen BioTherapeutics (Suzhou) for Acute Lymphoblastic Lymphoma: Likelihood of Approval

PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Acute Lymphoblastic Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - PA-317 in Acute Lymphoblastic Lymphoma

Data Insights

PA-317 by PersonGen BioTherapeutics (Suzhou) for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

PA-317 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....

Likelihood of Approval and Phase Transition Success Rate Model - PA-317 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy

Data Insights

TAA-05 by PersonGen BioTherapeutics (Suzhou) for Refractory Acute Myeloid Leukemia: Likelihood of Approval

TAA-05 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Refractory Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - TAA-05 in Refractory Acute Myeloid Leukemia

Data Insights

TAA-05 by PersonGen BioTherapeutics (Suzhou) for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

TAA-05 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Relapsed Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - TAA-05 in Relapsed Acute Myeloid Leukemia

Data Insights

UTAA-17 by PersonGen BioTherapeutics (Suzhou) for Relapsed Multiple Myeloma: Likelihood of Approval

UTAA-17 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Relapsed Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - UTAA-17 in Relapsed Multiple Myeloma

Data Insights

UTAA-17 by PersonGen BioTherapeutics (Suzhou) for Refractory Multiple Myeloma: Likelihood of Approval

UTAA-17 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Refractory Multiple Myeloma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - UTAA-17 in Refractory Multiple Myeloma